Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-course vs Long-course Tislelizumab With Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma
NCT07373990Phase 3Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2026
- Primary completion
- Apr 2028
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of tislelizumab in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT07373990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07373990.